Uncategorized

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation

Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for INGREZZA ® (valbenazine) oral granules, a new sprinkle formulation of INGREZZA.

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation Read More »

Mayo Clinic and GE HealthCare Enter Strategic Collaboration to Advance Innovation in Medical Imaging and Theranostics

Today, Mayo Clinic and GE HealthCare announce a strategic healthcare collaboration for research and product development programs aimed to transform the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies.

Mayo Clinic and GE HealthCare Enter Strategic Collaboration to Advance Innovation in Medical Imaging and Theranostics Read More »

Scroll to Top